Welcome to our dedicated page for Orexo AB (publ) news (Ticker: $ORXOY), a resource for investors and traders seeking the latest updates and insights on Orexo AB (publ) stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Orexo AB (publ)'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Orexo AB (publ)'s position in the market.
Rhea-AI Summary
Orexo AB plans to issue new senior secured callable floating rate social bonds worth SEK 500,000,000. The company aims to refinance existing bonds and finance acquisitions or investments. Orexo also announced a Tender Offer for existing bondholders at 100.750% of the nominal amount plus interest. The Tender Offer expires on March 14, 2024, subject to the successful issue of the New Social Bonds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Orexo and Sobi announced the advancement of their collaboration following a successful exploratory feasibility study with Orexo's AmorphOX drug delivery platform. The study confirmed the biomolecule's activity retention after formulation with AmorphOX. Orexo has patent applications for AmorphOX formulations related to biomolecules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
In the press release from February 8, 2024, Orexo AB reported a positive EBITDA in H2, setting the target for FY 2024. The total net revenues were SEK 166.0 m, with the US Pharma segment (Zubsolv® US) net revenues of SEK 151.3 m. The MODIA® study didn't meet the primary end-points, but showed high rates of treatment response. Robin Evers was elected as a board member, and the FDA accepted the New Drug Application filing for review of OX124, a high-dose rescue medication for opioid overdose with naloxone. The financial outlook for 2024 includes a 2-5% growth in the buprenorphine/naloxone market and positive EBITDA for the FY 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
News
Rhea-AI Summary
Orexo AB (publ.) announces the presentation of its nasal epinephrine powder product OX640 at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. The product is based on the proprietary AmorphOX drug delivery platform and has the potential to provide allergic patients with a needle-free, convenient, and rapidly acting allergy rescue product. Dr. Anne K Ellis, an esteemed expert in the field of allergy, will present the abstract at the high-profile late breaking oral abstract session.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Orexo AB (ORX) announces the NDA acceptance for OX124, a nasal rescue medication for opioid overdose, by the US FDA. OX124, based on Orexo´s amorphOX® platform, contains high-dose naloxone and targets synthetic opioid overdoses. The PDUFA date is set to July 15, 2024, with a potential US launch later that year. The medication's unique formulation and rapid absorption make it a promising solution to combat fatal opioid overdoses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Orexo, a pharmaceutical company based in Sweden, reported Q3 2023 financial results with total net revenues of SEK 156.1 million. The US Pharma segment generated net revenues of SEK 140.4 million. The company filed OX124, a high-dose rescue medication for opioid overdose, with the FDA. The MODIA® study showed high rates of treatment response. Orexo aims to reach EBITDA in balance for H2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Robin Evers joins Orexo AB's Board of Directors, replacing Henrik Kjaer Hansen. Evers brings 25 years of experience in the pharmaceutical industry and expertise in biologics and vaccines. Orexo focuses on pharmaceutical development with its scalable formulation platform amorphOX®. James Noble, Chairman of the Board, welcomes Evers and thanks Hansen for his contributions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Orexo appoints Nomination Committee for the upcoming Annual General Meeting in 2024. The committee will prepare proposals for various positions and fees, and shareholders can submit their proposals by February 24, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Orexo AB announces election of new board member and dismissal of current member at extraordinary general meeting. Remuneration to the board of directors to continue as previously resolved. Complete proposals available on Orexo's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Orexo reports top line results of study evaluating the efficacy of MODIA for the treatment of opioid use disorder
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Orexo AB (publ)
OTC:ORXOY
ORXOY Rankings
ORXOY Stock Data
51.75M
21.61M
Medicinal and Botanical Manufacturing
Manufacturing
United States of America
Uppsala